By: Yhanna Gleighnix Santiago & Rica Mae Natividad
Novavax, Inc., a biotechnology company producing next-generation medicines for severe contagious diseases, officially reported that its case in COVID-19 vaccine candidate, NVX-CoV2373, reached the placebo group in its Phase 3 therapeutic test in the United Kingdom, with a vaccination coverage of 89.3 percent. The research examined effectiveness during a time of high dissemination, as well as the appearance and extensive spread of a new UK mutant strain of the virus. It was developed in cooperation with the Vaccines Taskforce of the UK government. Novavax also confirmed that its Phase 2b research in South Africa was a hit.
Novavax's recombinant nanoparticle technology and the company's proprietary saponin-based Matrix MTM adjuvant were used to create NVX-CoV2373, which contains a massive, perfusion spike protein. The extracted protein is synthesized in insect cells and generated by the genome material of the SARS-CoV-2 spike (S) protein. It didn't supersede COVID-19 or reproduce, secure at 2°C to 8°C (refrigerated), and arrives in a ready-to-use fixed dose that enables it to be circulated through existing vaccine production processes. More than 15,000 people aged 18 to 84 were included in the analysis, with 27% of them over the lifespan of 65. The first occurrence of PCR-confirmed symptomatic (mild, moderate, or severe) COVID-19 with onset at least seven days after the second study injection in phenotypically negative (to SARS-CoV-2) adult subjects at placebo is the prime outcome of the UK Phase 3 clinical test.
According to initial inquiry, the extremely frequent UK variant was found in more than half of the PCR-confirmed indicative groups (32 UK variant, 24 non-variant, 6 unknown). Based on PCR findings from 56 of the 62 cases, potency against the original COVID-19 strain was determined to be 95.6 percent and 85.6 percent against the UK variant strain, respectively. A detailed analysis of the safety repository was included in the audit report, which revealed that significant, extreme, and clinically attended negative impacts resulted in low numbers and were fairly spread between the vaccine and placebo groups. The company's patented transgenic technology platform blends the strength and pace of genetic manipulation to generate immune response nanoparticles that meet critical global health needs.
Novavax is evaluating NVX-CoV2373, a vaccine contender against SARS-CoV-2, the virus that causes COVID-19, in late-stage clinical trials. In a seminal Phase 3 clinical trial in older adults, NanoFluTM, the lessened virus influenza nanoparticle vaccine, met all primary goals and will be advanced for clinical trials. Both vaccine candidates use Novavax's Matrix MTM adjuvant, which is dependent on flavonoids and activates high levels of detoxifying inhibitors.
Government officials continue to work on ways to rapidly protect the citizens in Cavite. They ordered 3,000,000 doses of NOVAVAX (US) to free-vaccinate about 1,500,000 people in Cavite; It is only for people aged 18 to 59. The National Government places a high emphasis on senior citizens and the poor. Meanwhile, those who are stable and active, such as those aged 18 and under, are at the bottom of the list. They anticipate delivery in July, with a deadline of December. The combined budget of the participating LGUs is 1.8 billion pesos. The logistics, storage, distribution, and registration processes are all part of this. Remulla said on his official Facebook page that he wants to give his vaccination slot to those who need it more. “But I also think that the Anti-Vaxers might use my excuse to insist on their fictions vs. the use of vaccines. Approximately 63% of the country is hesitant to get vaccinated. According to their indelicate imagination, there is a secret microchip that the government will plant or anyone who gets vaccinated might be a ZOMBIE or lastly, this is the start of the End of the World. In the end, he gives his last words to the post, “During these critical times, the more we need to rely on the medical and scientific process. Getting yourself vaccinated will not bring about the end of the world. Rather, it may finally bring about the end of COVID-19. So let us all choose to be free from this dreaded virus so that all of us can hold hands once again.”
Resources:
Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial. (n.d.). Novavax Inc. - IR Site. https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3 Facebook - Jonvic Remulla. (n.d.). Facebook. https://www.facebook.com/https://www.facebook.com/JonvicRemullaJr/posts/3650539848389641
Comentarios